{"filing":{"accession_number":"0001778922-26-000044","cik":"0001778922","ticker":"SGP","company_name":"SpyGlass Pharma, Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"sgp-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1778922/000177892226000044/sgp-20260806.htm"},"events":[{"id":25969,"run_id":23583,"accession_number":"0001778922-26-000044","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"SpyGlass Pharma issued a press release on August 6, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing Q2 2026 net loss of $19.9 million (vs. $8.7 million in Q2 2025), R\u0026D expenses of $10.9 million, G\u0026A expenses of $11.0 million, and cash position of $234.2 million. The filing explicitly states this is furnished pursuant to Item 2.02 (Results of Operations and Financial Condition) with the press release attached as Exhibit 99.1, which is the standard format for quarterly earnings releases.","company_name":"SpyGlass Pharma, Inc.","ticker":"SGP","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26922,"accession_number":"0001778922-26-000044","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"SpyGlass Pharma issued a press release on August 6, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing Q2 2026 net loss of $19.9 million (vs. $8.7 million in Q2 2025), R\u0026D expenses of $10.9 million, G\u0026A expenses of $11.0 million, and cash position of $234.2 million. The filing explicitly states this is furnished pursuant to Item 2.02 (Results of Operations and Financial Condition) with the press release attached as Exhibit 99.1, which is the standard format for quarterly earnings releases.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:50:57.324876+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26922,"accession_number":"0001778922-26-000044","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"SpyGlass Pharma issued a press release on August 6, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing Q2 2026 net loss of $19.9 million (vs. $8.7 million in Q2 2025), R\u0026D expenses of $10.9 million, G\u0026A expenses of $11.0 million, and cash position of $234.2 million. The filing explicitly states this is furnished pursuant to Item 2.02 (Results of Operations and Financial Condition) with the press release attached as Exhibit 99.1, which is the standard format for quarterly earnings releases.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:50:57.324876+00:00","company_name":"SpyGlass Pharma, Inc.","ticker":"SGP","filing_date":"2026-08-06"}]}